IL2 and infectious disease: We recommend that dendritic cells used in immunotherapy for cancer (or infectious diseases) be routinely screened for IL-2-producing DCs because inadvertent delivery of IL-2-producing DCs may undermine the effectiveness of DC-based therapy by promoting Treg suppressor function.